Elicio End Period Cash Flow from 2010 to 2024

ELTX Stock   4.88  0.20  3.94%   
Elicio Therapeutics End Period Cash Flow yearly trend continues to be fairly stable with very little volatility. End Period Cash Flow will likely drop to about 12 M in 2024. During the period from 2010 to 2024, Elicio Therapeutics End Period Cash Flow regression line of annual values had r-squared of  0.48 and arithmetic mean of  8,521,707. View All Fundamentals
 
End Period Cash Flow  
First Reported
2010-12-31
Previous Quarter
14.3 M
Current Value
12 M
Quarterly Volatility
2.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Elicio Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Elicio Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 391.6 K, Depreciation And Amortization of 828.2 K or Selling General Administrative of 6.8 M, as well as many indicators such as Price To Sales Ratio of 0.57, Dividend Yield of 0.0 or PTB Ratio of 3.89. Elicio financial statements analysis is a perfect complement when working with Elicio Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Elicio Therapeutics Correlation against competitors.
For more information on how to buy Elicio Stock please use our How to Invest in Elicio Therapeutics guide.

Latest Elicio Therapeutics' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Elicio Therapeutics over the last few years. It is Elicio Therapeutics' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Elicio Therapeutics' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

Elicio End Period Cash Flow Regression Statistics

Arithmetic Mean8,521,707
Geometric Mean8,150,890
Coefficient Of Variation34.16
Mean Deviation2,296,515
Median6,810,078
Standard Deviation2,911,255
Sample Variance8.5T
Range8.2M
R-Value0.70
Mean Square Error4.7T
R-Squared0.48
Significance0
Slope452,467
Total Sum of Squares118.7T

Elicio End Period Cash Flow History

202412 M
202314.3 M
20228.4 M
202110 M
202015 M

About Elicio Therapeutics Financial Statements

Elicio Therapeutics investors use historical fundamental indicators, such as Elicio Therapeutics' End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Elicio Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow14.3 M12 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Elicio Stock Analysis

When running Elicio Therapeutics' price analysis, check to measure Elicio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicio Therapeutics is operating at the current time. Most of Elicio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicio Therapeutics' price. Additionally, you may evaluate how the addition of Elicio Therapeutics to your portfolios can decrease your overall portfolio volatility.